A study from China also demonstrated that TP53 and KRAS mutations in lung adenocarcinoma might serve as a pair of potential predictive factors to guide anti-PD-1/PDL1 immunotherapy (25). The gene discussed is TP53; the disease is lung adenocarcinoma.